480 ARSENAL WAY, SUITE 100, WATERTOWN, MA
Acrivon Therapeutics Approves Amended 2022 Equity Incentive Plan
Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts
Annual Report to Security Holders
Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Termination of OncoSignature Diagnostic Agreement with Akoya Biosciences
Investor Presentation
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data
Q1
FY 2025
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload